Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 253

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics

Open access
Kumar, Shaji, Fonseca, Rafael, Ketterling, Rhett P., Dispenzieri, Angela, Lacy, Martha Q., Gertz, Morie A., Hayman, Suzanne R., Buadi, Francis K., Dingli, David, Knudson, Ryan A., Greenberg, Alexandra, Russell, Stephen J., Zeldenrust, Steven R., Lust, John A., Kyle, Robert A., Bergsagel, Leif, Rajkumar, S. Vincent·2012·Blood
DOI 10.1182/blood-2011-11-390658
Open this paper in CoChat — free account

Abstract

Routine incorporation of FISH into multiple myeloma (MM) diagnostic testing has led to a better appreciation of the heterogeneity of genetic abnormalities associated with this disease. We studied a group of 484 patients with newly diagnosed symptomatic MM to better understand the prevalence of the various abnormalities and the prognostic significance of the overlapping abnormalities. A translocation involving the IgH locus and 1 of the 5 recurrent partner chromosomes was seen in 161 (33%) patients, and 275 (57%) had trisomy of at least 1 odd-numbered chromosome. High-risk FISH, defined as the presence of t(4;14), t(14;16), t(14;20), or loss of P53, was seen in 115 (24%) patients; the median overall survival for this group was 3.9 years, compared with “not reached” for standard-risk patients (P < .001). Among the patients with high-risk FISH, 49 patients who also had at least 1 trisomy had a median overall survival that was not reached, compared with 3 years for high-risk patients without a concurrent trisomy (P = .01). Based on the current findings, we conclude that the presence of trisomies in patients with t(4;14), t(14;16), t(14;20), or p53 deletion abnormalities in MM ameliorates the usual adverse impact associated with these prognostic markers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-11-390658

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 27

  1. Fonseca, 2004, Genetics and cytogenetics of multiple myeloma: a workshop report., Cancer Res, 64, 1546, 10.1158/0008-5472.CAN-03-2876 · DOI · Paper page
  2. Fonseca, 2009, International Myeloma Working Group molecular classification of multiple myeloma: spotlight review., Leukemia, 23, 2210, 10.1038/leu.2009.174 · DOI · Paper page
  3. Avet-Loiseau, 2007, Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome., Blood, 109, 3489, 10.1182/blood-2006-08-040410 · DOI · Paper page
  4. Pérez-Simón, 1998, Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes., Blood, 91, 3366, 10.1182/blood.V91.9.3366 · DOI · Paper page
  5. Greipp, 1993, Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma., Blood, 81, 3382, 10.1182/blood.V81.12.3382.3382 · DOI · Paper page
  6. Fonseca, 2003, Clinical and biologic implications of recurrent genomic aberrations in myeloma., Blood, 101, 4569, 10.1182/blood-2002-10-3017 · DOI · Paper page
  7. Drach, 1995, Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization., Cancer Res, 55, 3854
  8. Chiecchio, 2006, Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma., Leukemia, 20, 1610, 10.1038/sj.leu.2404304 · DOI · Paper page
  9. Chng, 2006, Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations., Leukemia, 20, 807, 10.1038/sj.leu.2404172 · DOI
  10. Facon, 2001, Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy., Blood, 97, 1566, 10.1182/blood.V97.6.1566 · DOI · Paper page
  11. Chang, 2005, p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation., Blood, 105, 358, 10.1182/blood-2004-04-1363 · DOI · Paper page
  12. Drach, 1998, Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy., Blood, 92, 802, 10.1182/blood.V92.3.802 · DOI · Paper page
  13. Kröger, 2004, Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation., Blood, 103, 4056, 10.1182/blood-2003-12-4435 · doi:10.1182/blood-2003-12-4435
  14. Shaughnessy, 2007, Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics., Br J Haematol, 137, 530, 10.1111/j.1365-2141.2007.06586.x · doi:10.1111/j.1365-2141.2007.06586.x
  15. Kapoor, 2010, Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie., Mayo Clin Proc, 85, 532, 10.4065/mcp.2009.0677 · DOI
  16. Gertz, 2005, Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy., Blood, 106, 2837, 10.1182/blood-2005-04-1411 · DOI · Paper page
  17. Kumar, 2009, Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines., Mayo Clinic Proceedings, 84, 1095, 10.4065/mcp.2009.0603 · DOI · Paper page
  18. Chng, 2005, A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS., Blood, 106, 2156, 10.1182/blood-2005-02-0761 · DOI
  19. Zhan, 2008, High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone., Blood, 111, 968, 10.1182/blood-2007-10-119321 · DOI
  20. Kumar, 2011, Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone., Blood, 118, 4359, 10.1182/blood-2011-03-342089 · DOI
  21. Moreau, 2007, Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials., Leukemia, 21, 2020, 10.1038/sj.leu.2404832 · DOI
  22. Chng, 2008, Do beta2 microglobulin levels affect survival of newly diagnosed myeloma patients with translocation t(4;14) or 17p13 deletion treated with conventional chemotherapy?, Leukemia, 22, 1080, 10.1038/sj.leu.2405009 · doi:10.1038/sj.leu.2405009
  23. Avet-Loiseau, 2010, Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)., J Clin Oncol, 28, 4630, 10.1200/JCO.2010.28.3945 · DOI · Paper page
  24. Chng, 2007, Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling., Cancer Res, 67, 2982, 10.1158/0008-5472.CAN-06-4046 · DOI · Paper page
  25. Wuilleme, 2005, Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma., Leukemia, 19, 275, 10.1038/sj.leu.2403586 · DOI
  26. Ng, 1997, Frequent hypermethylation of p16 and p15 genes in multiple myeloma., Blood, 89, 2500, 10.1182/blood.V89.7.2500 · DOI · Paper page
  27. Chng, 2006, Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma., Genes Chromosomes Cancer, 45, 1111, 10.1002/gcc.20375 · DOI

Cited by

See all 253

Metadata

Authors
Kumar, S., Fonseca, R., Ketterling, R. P., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Hayman, S. R., Buadi, F. K., Dingli, D., Knudson, R. A., Greenberg, A., Russell, S. J., Zeldenrust, S. R., Lust, J. A., Kyle, R. A., Bergsagel, L., & Rajkumar, S. V.
Venue
Blood
Publisher
American Society of Hematology
Published
2012-03-01
Volume
119
Issue
9
Pages
2100-2105
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood-2011-11-390658
OpenAlex
W2040889135
Cited by
253
References
1
FWCI
13.83
Type
journal article
Language
en
Update notices
erratum (2014-03-06)
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. https://app.cochat.ai/papers/10.1182/blood-2011-11-390658
The paper
Kumar, S., Fonseca, R., Ketterling, R. P., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Hayman, S. R., Buadi, F. K., Dingli, D., Knudson, R. A., Greenberg, A., Russell, S. J., Zeldenrust, S. R., Lust, J. A., Kyle, R. A., Bergsagel, L., & Rajkumar, S. V. (2012). Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. https://doi.org/10.1182/blood-2011-11-390658

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.